Investigating the relationship between BRAF status and melanoma response to anti-angiogenic therapy

Investigating the relationship between BRAF status and melanoma response to anti-angiogenic therapy

<p>A large phase 3 trial (AVAST-M) assessing bevacizumab as adjuvant therapy for melanoma has shown that patients with BRAF V600E melanomas had improved disease-free interval compared to the wild-type (WT) BRAF population, suggesting a differential sensitivity of BRAF V600E to Bevacizumab. Bev...

Fuld beskrivelse

Bibliografiske detaljer
Hovedforfatter:	Guo, L
Andre forfattere:	Macaulay, V
Format:	Thesis
Udgivet:	2019

Lignende værker

Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment
af: Sebastian A. Wohlfeil, et al.
Udgivet: (2022-02-01)

Braf-Mutant Melanomas: Biology and Therapy
af: Elvira Pelosi, et al.
Udgivet: (2024-12-01)

Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
af: Michael A. Davies
Udgivet: (2014-01-01)

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma
af: M. Amini-Adle, et al.
Udgivet: (2018-07-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
af: Azad Saei, et al.
Udgivet: (2018-09-01)

The relationship of clinical and morphological parameters with the BRAF status of the tumor in patients with stage I skin melanoma
af: K. S. Titov, et al.
Udgivet: (2024-09-01)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
af: Zhen-Ling Liu, et al.
Udgivet: (2023-05-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
af: O. I. Kit, et al.
Udgivet: (2016-06-01)

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma
af: Camille Fuselier, et al.
Udgivet: (2021-03-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
af: Sara Bjursten, et al.
Udgivet: (2019-11-01)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
af: Muna Al Hashmi, et al.
Udgivet: (2020-05-01)

Nephrotoxicity of Anti-Angiogenic Therapies
af: Margaux Van Wynsberghe, et al.
Udgivet: (2021-04-01)

Tumor angiogenesis and anti-angiogenic therapy
af: Ziheng Guo, et al.
Udgivet: (2024-09-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
af: Yu. S. Shakh-Paronyants, et al.
Udgivet: (2023-03-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
af: Nakul Dar, et al.
Udgivet: (2023-08-01)

Combined therapy of dabrafenib and an anti-HER2 antibody–drug conjugate for advanced BRAF-mutant melanoma
af: Weisong Li, et al.
Udgivet: (2024-04-01)

Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma
af: Riyue Bao, et al.
Udgivet: (2025-02-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
af: Zeynep Eroglu, et al.
Udgivet: (2016-01-01)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma
af: Hee Kyung Kim, et al.
Udgivet: (2016-12-01)

A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors
af: Molly C. Peters, et al.
Udgivet: (2018-01-01)

Phosphoproteomic analysis of cell-based resistance to BRAF inhibitor therapy in melanoma
af: Robert eParker, et al.
Udgivet: (2015-05-01)

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
af: Chi Yan, et al.
Udgivet: (2022-01-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
af: Dolinsek Tanja, et al.
Udgivet: (2016-09-01)

Numerical Investigation on the Anti-Angiogenic Therapy-Induced Normalization in Solid Tumors
af: Mahya Mohammadi, et al.
Udgivet: (2022-02-01)

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
af: Thomas Botton, et al.
Udgivet: (2019-10-01)

Sensitivity to anti-BRAF therapy: Lost in translation
af: Kalkavan, H, et al.
Udgivet: (2015)

Sensitivity to anti-BRAF therapy: lost in translation.
af: Kalkavan, H, et al.
Udgivet: (2015)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
af: Clare Judith Stones, et al.
Udgivet: (2013-05-01)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
af: Lisa Zimmer, et al.
Udgivet: (2022-07-01)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
af: Caitlyn N. Myrdal, et al.
Udgivet: (2020-01-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
af: Sivakamavalli Jeyachandran
Udgivet: (2024-06-01)

The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies
af: Saber Imani, et al.
Udgivet: (2024-11-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
af: Raphael Reinhard, MD, et al.
Udgivet: (2018-03-01)

A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1
af: OPhir Nave, et al.
Udgivet: (2022-12-01)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
af: Ryan J. Sullivan, et al.
Udgivet: (2011-01-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
af: Polsky David, et al.
Udgivet: (2004-12-01)

Mathematical models of anti-angiogenic therapy and vessel normalisation
af: Hutchinson, L
Udgivet: (2017)

Surgical series of metastatic cerebral melanoma: Clinical association of resection, BRAF-mutation status, and survival
af: M.J. Colditz, et al.
Udgivet: (2021-06-01)

Biomarkers of anti-angiogenic therapy in breast cancer
af: Mehta, S
Udgivet: (2014)

Trends and Challenges in Tumor Anti-Angiogenic Therapies
af: József Jászai, et al.
Udgivet: (2019-09-01)